Abstract
Acyclovir is acycloguanosine antiviral which is used in the treatment of herpes simplex keratitis. Acyclovir drops are required to be instilled frequently in the eyes (5 times a day), as they exhibit short precorneal residence time and poor bioavailability due to rapid elimination induced by tear turnover, blinking, and drainage of formulation. Moreover, application of its ointment leads to blurring of vision which results into patient non compliance. It was, therefore, thought worthwhile to develop an in-situ gel formulation using a suitable phase transition polymer to effectively deliver the drug into eyes with sustained and prolonged release and enhanced drug bioavailability leading to effective management of herpes simplex keratitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmaceutical Sciences and Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
